Whole Genome Amplification

Rubicon announces breakthrough in drug development

Published in Gene Therapy Weekly, July 25th, 2002

Rubicon Genomics, Inc., announced it has achieved a technical breakthrough with its OmniPlex technology for whole genome amplification (WGA) that enables large-scale pharmacogenomics and drug target discovery projects to be conducted utilizing less than a single drop of blood from each clinical subject.

"Rubicon OmniPlex WGA will change the structure of population studies and clinical trials, decreasing the cost and time for drug development," stated Thomas A. Collet, president and CEO of Rubicon Genomics. "Many of the large-scale population and clinical single nucleotide polymorphism (SNP) studies have encountered hurdles due to the lack of sufficient DNA to score...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry